OBJECTIVE: The aim of this guideline is to assist FPs and other primary care providers with recognizing features that should raise their suspicion about the presence of prostate cancer in their patients. COMPOSITION OF THE COMMITTEE: Committee members were selected from among the regional primary care leads from the Cancer Care Ontario Provincial Primary Care and Cancer Network and from among the members of the Cancer Care Ontario Genitourinary Cancer Disease Site Group. METHODS: This guideline was developed through systematic review of the evidence base, synthesis of the evidence, and formal external review involving Canadian stakeholders to validate the relevance of recommendations. REPORT: Evidence-based guidelines were developed to improve the management of patients presenting with clinical features of prostate cancer within the Canadian context. CONCLUSION: These guidelines might lead to more timely and appropriate referrals and might also be of value for informing the development of prostate cancer diagnostic programs and for helping policy makers to ensure appropriate resources are in place.
OBJECTIVE: The aim of this guideline is to assist FPs and other primary care providers with recognizing features that should raise their suspicion about the presence of prostate cancer in their patients. COMPOSITION OF THE COMMITTEE: Committee members were selected from among the regional primary care leads from the Cancer Care Ontario Provincial Primary Care and Cancer Network and from among the members of the Cancer Care Ontario Genitourinary Cancer Disease Site Group. METHODS: This guideline was developed through systematic review of the evidence base, synthesis of the evidence, and formal external review involving Canadian stakeholders to validate the relevance of recommendations. REPORT: Evidence-based guidelines were developed to improve the management of patients presenting with clinical features of prostate cancer within the Canadian context. CONCLUSION: These guidelines might lead to more timely and appropriate referrals and might also be of value for informing the development of prostate cancer diagnostic programs and for helping policy makers to ensure appropriate resources are in place.
Authors: J Curtis Nickel; Carlos E Méndez-Probst; Thomas F Whelan; Ryan F Paterson; Hassan Razvi Journal: Can Urol Assoc J Date: 2010-10 Impact factor: 1.862
Authors: G P Browman; M N Levine; E A Mohide; R S Hayward; K I Pritchard; A Gafni; A Laupacis Journal: J Clin Oncol Date: 1995-02 Impact factor: 44.544
Authors: Robert K Nam; Michael W Kattan; Joseph L Chin; John Trachtenberg; Rajiv Singal; Ricardo Rendon; Laurence H Klotz; Linda Sugar; Christopher Sherman; Jonathan Izawa; David Bell; Aleksandra Stanimirovic; Vasundara Venkateswaran; Eleftherios P Diamandis; Changhong Yu; D Andrew Loblaw; Steven A Narod Journal: J Clin Oncol Date: 2011-06-20 Impact factor: 44.544
Authors: Amr M Hawary; Hazel E Warburton; Richard J Brough; Gerald N Collins; Stephen C Brown; Patrick H O'Reilly; Adebanji Ab Adeyoju Journal: Ann R Coll Surg Engl Date: 2008-09 Impact factor: 1.891
Authors: Robert K Nam; Ants Toi; Laurence H Klotz; John Trachtenberg; Michael A S Jewett; Sree Appu; D Andrew Loblaw; Linda Sugar; Steven A Narod; Michael W Kattan Journal: J Clin Oncol Date: 2007-08-20 Impact factor: 44.544
Authors: M R Quinlan; B J O'Daly; M F O'Brien; S Gardner; G Lennon; D W Mulvin; D M Quinlan Journal: Ir J Med Sci Date: 2009-04-15 Impact factor: 1.568
Authors: Christopher J McNally; Joanne Watt; Mary Jo Kurth; John V Lamont; Tara Moore; Peter Fitzgerald; Hardev Pandha; Declan J McKenna; Mark W Ruddock Journal: Front Oncol Date: 2022-05-19 Impact factor: 5.738